Correlation between levels of perceived stress and depressive symptoms in the functional disability of patients with fibromyalgia.

OBJECTIVE: The aim of this study was to evaluate the factors that are most correlated with the levels of functional disability in patients with fibromyalgia. METHODS: This is a cross-sectional descriptive study in which 42 patients diagnosed with fibromyalgia according to the criteria of the American College of Rheumatology reported their status using the following questionnaires: the Beck Depression Inventory, the Perceived Stress Scale 14, the Revised Fibromyalgia Impact Questionnaire, the Visual Analog Pain Scale, and the Health Assessment Questionnaire. RESULTS: Moderate to severe levels of depression (Beck Depression Inventory: 22.35±10.39), moderate to severe functional disability (Health Assessment Questionnaire: 1.28±0.58), and high levels of stress (Perceived Stress Scale 14: 31.59±10.02) were found. The correlation adjusted by multiple regression as a function of the Health Assessment Questionnaire indicated a negligible to weak positive correlation with perceived stress (r=0.11), while a moderately strong positive correlation was observed with the Visual Analog Pain Scale (r=0.55). Regarding physical exercise, one of the pillars of the treatment, a moderate negative correlation was found with the Health Assessment Questionnaire (r=-0.4). CONCLUSION: The pain levels were moderately influenced by depression severity. The factors most linked to functional disability are due to the pain levels but not to the perception of stress.

Correlation between levels of perceived stress and depressive symptoms in the functional disability of patients with fibromyalgia

SUMMARY OBJECTIVE: The aim of this study was to evaluate the factors that are most correlated with the levels of functional disability in patients with fibromyalgia. METHODS: This is a cross-sectional descriptive study in which 42 patients diagnosed with fibromyalgia according to the criteria of the American College of Rheumatology reported their status using the following questionnaires: the Beck Depression Inventory, the Perceived Stress Scale 14, the Revised Fibromyalgia Impact Questionnaire, the Visual Analog Pain Scale, and the Health Assessment Questionnaire. RESULTS: Moderate to severe levels of depression (Beck Depression Inventory: 22.35±10.39), moderate to severe functional disability (Health Assessment Questionnaire: 1.28±0.58), and high levels of stress (Perceived Stress Scale 14: 31.59±10.02) were found. The correlation adjusted by multiple regression as a function of the Health Assessment Questionnaire indicated a negligible to weak positive correlation with perceived stress (r=0.11), while a moderately strong positive correlation was observed with the Visual Analog Pain Scale (r=0.55). Regarding physical exercise, one of the pillars of the treatment, a moderate negative correlation was found with the Health Assessment Questionnaire (r=-0.4). CONCLUSION: The pain levels were moderately influenced by depression severity. The factors most linked to functional disability are due to the pain levels but not to the perception of stress.

Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology.

Scientists and health professionals are exhaustively trying to contain the coronavirus disease 2019 (COVID-19) pandemic by elucidating viral invasion mechanisms, possible drugs to prevent viral infection/replication, and health cares to minimize individual exposure. Although neurological symptoms are being reported worldwide, neural acute and long-term consequences of SARS-CoV-2 are still unknown. COVID-19 complications are associated with exacerbated immunoinflammatory responses to SARS-CoV-2 invasion. In this scenario, pro-inflammatory factors are intensely released into the bloodstream, causing the so-called "cytokine storm". Both pro-inflammatory factors and viruses may cross the blood-brain barrier and enter the central nervous system, activating neuroinflammatory responses accompanied by hemorrhagic lesions and neuronal impairment, which are largely described processes in psychiatric disorders and neurodegenerative diseases. Therefore, SARS-CoV-2 infection could trigger and/or worse brain diseases. Moreover, patients with central nervous system disorders associated to neuroimmune activation (e.g. depression, Parkinson's and Alzheimer's disease) may present increased susceptibility to SARS-CoV-2 infection and/or achieve severe conditions. Elevated levels of extracellular ATP induced by SARS-CoV-2 infection may trigger hyperactivation of P2X7 receptors leading to NLRP3 inflammasome stimulation as a key mediator of neuroinvasion and consequent neuroinflammatory processes, as observed in psychiatric disorders and neurodegenerative diseases. In this context, P2X7 receptor antagonism could be a promising strategy to prevent or treat neurological complications in COVID-19 patients.

Effects of biperiden on the treatment of cocaine/crack addiction: a randomised, double-blind, placebo-controlled trial.

Cocaine use affects approximately 13.4 million people, or 0.3% of the world's population between 15 and 64 years of age. Several authors have described drug addiction as a disease of the brain reward system. Given that the cholinergic system impacts reward mechanisms and drug self-administration, acetylcholine (ACh) might play an important role in the cocaine addiction process. We evaluated the efficacy of biperiden (a cholinergic antagonist) in reducing craving and the amount used, and in increasing compliance with treatment for cocaine/crack addiction. It was a study double-blind, randomised, placebo-controlled, 8-week trial of 111 cocaine or crack addicted male patients between 18 and 50 years old. Two groups were compared: placebo (n=55) or biperiden (n=56) combined with weekly sessions of brief group cognitive-behavioural therapy. The efficacy of treatment was evaluated according to the patients' compliance and several instruments: the Minnesota Cocaine Craving Scale, the Beck Depression and Anxiety Scales and a questionnaire assessing the amount of drug used. All of the patients attended weekly sessions for two months. We analysed the data considering the patients' intention to treat based on our last observation. Of the 56 patients in the biperiden group, 24 completed the treatment (42.8%) compared with only 11 patients in the placebo group (20%), which was a significant difference (p=0.009). Compliance with treatment was 118% higher in the biperiden group, which was also the group that presented a statistically significant reduction in the amount of cocaine/crack use (p<0.001). There was statistically significant difference between the craving score in the biperiden group. Pharmacological blockade of the cholinergic system with biperiden is a promising alternative to treat cocaine/crack addiction, helping patients to reduce the amount used and improving compliance with psychotherapy treatment.

Factors associated with depressive symptoms in a sample of Brazilian medical students / Fatores associados a sintomas depressivos entre estudantes de medicina da UNILUS

OBJECTIVES: 1 - Verify the prevalence of depressive symptoms in first to fourth-year medical students using the Beck Depression Inventory (BDI). 2 - Establish correlations between target factors and higher or lower BDI scores. 3 - Investigate the relationship between the prevalence of depressive symptoms and the demand for psychological care offered by the Centro Universitário Lusíada. METHOD: Cross-sectional study of 290 first to fourth-year medical students; implementation of the BDI, socio-demographic survey, and evaluation of satisfaction with progress. RESULTS: The study sample was 59 percent female and 41 percent male. Mean BDI was 6.3 (SD 5.8). Overall prevalence of depressive symptoms was 23.1 percent. The following associations were statistically significant (p<0.05): among students for whom the course failed to meet original expectations, who were dissatisfied with the course, or who came from the interior of the State (20.5 percent, 12.5 percent, and 24.4 percent of the total sample, respectively), for 40 percent, 36.1 percent and 36.4 percent, respectively, the BDI was consistent with some degree of depression. CONCLUSION: The study showed that there is higher prevalence of depressive symptoms in medical students than in the general population

OBJETIVOS: 1- Verificar prevalência de sintomas depressivos nos estudantes de medicina do 1º a 4º ano através do Inventário de Depressão de Beck (IDB). 2- Estabelecer correlações entre os fatores questionados e a incidência de maior ou menor pontuação no IDB. 3- Investigar relação entre a prevalência de sintomas depressivos e a procura por atendimento psicológico oferecido pela Universidade Lusíada. MÉTODO: Desenho transversal realizado com 290 acadêmicos do curso de medicina, do 1º ao 4º ano. Realizada aplicação do IDB, questionário sócio-demográfico e avaliação sobre satisfação com curso. RESULTADOS: Da amostra estudada, 59 por cento sãomulheres e 41 por cento homens. O escore médio do IDB foi de 6,3 com DP de 5,8. Aprevalência total desintomas depressivos foi de 23,1 por cento. As seguintes relaçõesapresentaram significância estatística (P<0,05): Dosestudantes queafirmam que o curso não corresponde às expectativas iniciais,dosestudantes insatisfeitos com o curso e dosestudantes procedentes do Interior do Estado(20,5 por cento; 12,5 por centoe 24,4 por cento da amostra total, respectivamente), 40 por cento, 36,1 por cento e 36,4 por cento respectivamente, tem escore compatível com algum grau de depressão. CONCLUSÃO: O presente estudo mostrou que há maior prevalência de sintomas depressivos nos estudantes de Medicina que na população geral

A acurácia da Escala de Experiência Sexual do Arizona (ASEX) para identificar disfunção sexual em pacientes do espectro da esquizofrenia / The accuracy of the Arizona Sexual Experience Scale (ASEX) to identify sexual dysfunction in patients of the schizophrenia spectrum

CONTEXTO: A disfunção sexual é frequente entre pacientes com esquizofrenia, sendo relatada como um dos mais incômodos efeitos adversos dos antipsicóticos, e está diretamente relacionada com adesão ao tratamento. OBJETIVOS: a) avaliar a acurácia da Escala de Experiência Sexual do Arizona (ASEX) para identificar a disfunção sexual; b) avaliar a frequência da disfunção sexual em uma amostra de pacientes do espectro da esquizofrenia em tratamento com antipsicóticos; e c) investigar o efeito dos diferentes antipsicóticos na função sexual. MÉTODO: Pacientes ambulatoriais com esquizofrenia ou transtorno esquizoafetivo foram entrevistados por meio de questionários: ASEX e escala Dickson-Glazer (DGSFi) para avaliação do funcionamento sexual, em uma única entrevista. RESULTADOS: Cento e trinta e sete pacientes foram entrevistados. A sensibilidade e a especificidade da ASEX em relação à DGSFi foram: 80,8 por cento (95 por cento IC = 70,0 por cento-88,5 por cento) e 88,1 por cento (95 por cento IC = 76,5 por cento-94,7 por cento), e a taxa de classificação incorreta foi 9,5 por cento. A curva ROC comparando a pontuação da ASEX e da DGSFi revelou valor de 0,93 (IC = 0,879-0,970) com o ponto de corte da ASEX encontrado sendo 14/15. A disfunção sexual foi mais alta entre as mulheres (79,2 por cento) que nos homens (33,3 por cento) (χ2 = 27,41, gl = 1, p < 0,001). CONCLUSÃO: Os pacientes em tratamento com antipsicóticos mostraram alta frequência de queixas sexuais e a ASEX provou ser um instrumento eficaz para identificar disfunção sexual em amostra de pacientes ambulatoriais do espectro da esquizofrenia. As mulheres apresentaram frequência mais alta de disfunção, e desejo sexual e habilidade para alcançar orgasmo foram as áreas mais afetadas. O uso de antipsicóticos, principalmente o uso de combinações, foi associado com piora do funcionamento sexual.

BACKGROUND: Sexual dysfunction is frequent in patients with schizophrenia, it is reported as one of the most distressing antipsychotic's adverse effects and it is directly related to treatment compliance. OBJECTIVES: a) to evaluate the accuracy of the Arizona Sexual Experience Scale (ASEX) to identify sexual dysfunction; b) to assess the frequency of sexual dysfunction in a sample of outpatients with schizophrenia and schizoaffective disorder under antipsychotic therapy; and c) to investigate the effect of different antipsychotics on sexual function. METHOD: Outpatients with schizophrenia or schizoaffective disorder were asked to fulfill both the ASEX and the Dickson Glazer Scale for the Assessment of Sexual Functioning Inventory (DGSFi) at a single interview. RESULTS: 137 patients were interwied. The sensitivity and specificity of the ASEX in relation to DGSFi were: 80.8 percent, (95 percent CI = 70.0 percent-88.5 percent) and 88.1 percent (95 percent CI = 76.5 percent-94.7 percent), and the misclassification rate was 9.5 percent. The ROC curve comparing the ASEX and the DGSFi scores revealed a value of 0.93 (CI = 0.879-0.970), with the optimum cut-off point of ASEX being 14/15. Sexual dysfunction measured was higher in females (79.2 percent) than in males (33.3 percent) (χ2 = 27.41, d.f. = 1, p < 0.001). DISCUSSION: Patients under antipsychotic treatment showed a high level of sexual complaints, and the ASEX proved to be an accurate instrument to identify sexual dysfunction in an outpatient sample of patients with schizophrenia spectrum. Females showed a higher frequency of sexual dysfunctions and sexual drive and ability to reach orgasm were the most affected areas. The use of antipsychotics, especially the combinations, was more likely to impair sexual functioning.